Neon Therapeutics (NTGN) Stock Price, News & Analysis

Company Overview

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $3.07 to $3.07
• 50-Day Range: $2.77 to $3.07
• 52-Week Range: $0.88 to $6.25
• Volume: N/A
• Average Volume: 516,108 shs
• Market Capitalization: $88.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NTGN Stock Analysis - Frequently Asked Questions

How were Neon Therapeutics' earnings last quarter?

Neon Therapeutics Inc (NASDAQ:NTGN) issued its earnings results on Monday, March, 2nd. The company reported ($0.63) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.03.

When did Neon Therapeutics IPO?

Neon Therapeutics (NTGN) raised $101 million in an initial public offering (IPO) on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager.

What other stocks do shareholders of Neon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neon Therapeutics investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Sorrento Therapeutics (SRNE), Aduro Biotech (ADRO) and Altimmune (ALT).

Company Calendar

• Last Earnings: 3/02/2020
• Today: 5/24/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NTGN
• CIK: N/A
• Web: www.neontherapeutics.com
• Phone: 617-337-4701
• Fax: N/A
• Employees: 102
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-79,780,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -199.09%
• Return on Assets: -137.14%

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 1.58
• Quick Ratio: 3.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.50 per share
• Price / Book: 6.14

Miscellaneous

• Outstanding Shares: 28,967,000
• Free Float: N/A
• Market Cap: $88.93 million
• Optionable: Not Optionable
• Beta: -0.81